Redeye updates its view on Nanologica following what we view as an undramatic Q3 2025 report. While the cash position continues to pressure the share, operational momentum has improved materially. Since production stabilized in September, Nanologica has announced three new orders, signaling improving commercial traction and supporting a positive outlook for Q4 sales.
